Concepts (258)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 76 | 2021 | 262 | 11.140 |
Why?
|
| Anti-Asthmatic Agents | 12 | 2020 | 39 | 2.650 |
Why?
|
| Adrenal Cortex Hormones | 14 | 2021 | 121 | 2.020 |
Why?
|
| Severity of Illness Index | 28 | 2021 | 883 | 1.930 |
Why?
|
| Phenotype | 24 | 2021 | 644 | 1.850 |
Why?
|
| Sputum | 9 | 2021 | 15 | 1.370 |
Why?
|
| Bronchodilator Agents | 12 | 2021 | 49 | 1.250 |
Why?
|
| Lung | 12 | 2021 | 268 | 1.160 |
Why?
|
| Bronchoscopy | 4 | 2019 | 47 | 1.000 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 6 | 2021 | 149 | 1.000 |
Why?
|
| Eosinophils | 10 | 2021 | 29 | 0.980 |
Why?
|
| Forced Expiratory Volume | 19 | 2020 | 89 | 0.860 |
Why?
|
| Adult | 50 | 2021 | 9589 | 0.810 |
Why?
|
| Humans | 79 | 2021 | 32975 | 0.790 |
Why?
|
| Cluster Analysis | 6 | 2019 | 126 | 0.780 |
Why?
|
| Neutrophils | 5 | 2020 | 110 | 0.770 |
Why?
|
| Adolescent | 29 | 2020 | 3644 | 0.720 |
Why?
|
| Male | 56 | 2021 | 19757 | 0.700 |
Why?
|
| Female | 56 | 2021 | 20379 | 0.690 |
Why?
|
| Respiratory Function Tests | 14 | 2021 | 100 | 0.680 |
Why?
|
| Dyspnea | 2 | 2019 | 35 | 0.640 |
Why?
|
| Cough | 1 | 2019 | 21 | 0.600 |
Why?
|
| Middle Aged | 38 | 2021 | 12204 | 0.600 |
Why?
|
| Biological Products | 1 | 2020 | 77 | 0.580 |
Why?
|
| Young Adult | 19 | 2020 | 2743 | 0.570 |
Why?
|
| Bronchi | 7 | 2021 | 34 | 0.570 |
Why?
|
| Leukocyte Count | 5 | 2020 | 48 | 0.550 |
Why?
|
| Hypersensitivity | 2 | 2017 | 25 | 0.530 |
Why?
|
| Glucocorticoids | 5 | 2020 | 151 | 0.530 |
Why?
|
| Albuterol | 6 | 2019 | 19 | 0.530 |
Why?
|
| Immunologic Factors | 1 | 2017 | 51 | 0.510 |
Why?
|
| Immunotherapy | 1 | 2017 | 94 | 0.500 |
Why?
|
| Child | 22 | 2019 | 2479 | 0.500 |
Why?
|
| Smoking | 2 | 2021 | 531 | 0.490 |
Why?
|
| Bronchoalveolar Lavage Fluid | 6 | 2020 | 59 | 0.470 |
Why?
|
| Administration, Inhalation | 11 | 2019 | 54 | 0.460 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2020 | 1068 | 0.440 |
Why?
|
| Immunoglobulin E | 8 | 2020 | 36 | 0.440 |
Why?
|
| Cohort Studies | 13 | 2021 | 1852 | 0.410 |
Why?
|
| Receptors, Adrenergic, beta-2 | 4 | 2019 | 23 | 0.380 |
Why?
|
| Aged | 19 | 2021 | 10638 | 0.360 |
Why?
|
| Granulocytes | 3 | 2021 | 11 | 0.360 |
Why?
|
| European Continental Ancestry Group | 9 | 2019 | 1163 | 0.340 |
Why?
|
| Nitric Oxide | 7 | 2019 | 111 | 0.320 |
Why?
|
| Practice Guidelines as Topic | 3 | 2012 | 412 | 0.310 |
Why?
|
| Alendronate | 2 | 2019 | 11 | 0.300 |
Why?
|
| Epithelial Cells | 3 | 2019 | 129 | 0.290 |
Why?
|
| Genome-Wide Association Study | 5 | 2016 | 551 | 0.290 |
Why?
|
| Inflammation | 4 | 2021 | 542 | 0.280 |
Why?
|
| African Americans | 8 | 2019 | 1425 | 0.280 |
Why?
|
| Adrenergic beta-Agonists | 4 | 2019 | 30 | 0.270 |
Why?
|
| Gene Expression | 3 | 2021 | 336 | 0.260 |
Why?
|
| Age of Onset | 4 | 2012 | 92 | 0.260 |
Why?
|
| Cytokines | 2 | 2020 | 247 | 0.250 |
Why?
|
| Longitudinal Studies | 5 | 2021 | 780 | 0.250 |
Why?
|
| Interleukin-5 | 2 | 2020 | 5 | 0.240 |
Why?
|
| Comorbidity | 5 | 2019 | 573 | 0.240 |
Why?
|
| Case-Control Studies | 7 | 2019 | 880 | 0.230 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 3 | 2019 | 16 | 0.230 |
Why?
|
| Disease Progression | 2 | 2017 | 594 | 0.220 |
Why?
|
| Age Factors | 5 | 2017 | 1202 | 0.220 |
Why?
|
| Breath Tests | 6 | 2019 | 17 | 0.220 |
Why?
|
| Respiratory Mucosa | 2 | 2021 | 12 | 0.210 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 4066 | 0.210 |
Why?
|
| United States | 11 | 2019 | 4133 | 0.200 |
Why?
|
| Sex Factors | 2 | 2018 | 685 | 0.190 |
Why?
|
| Scopolamine Derivatives | 2 | 2013 | 5 | 0.190 |
Why?
|
| Prospective Studies | 5 | 2019 | 2338 | 0.180 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 308 | 0.180 |
Why?
|
| Double-Blind Method | 7 | 2019 | 543 | 0.180 |
Why?
|
| Vital Capacity | 4 | 2020 | 42 | 0.180 |
Why?
|
| Arginine | 2 | 2012 | 18 | 0.170 |
Why?
|
| Drug Resistance | 2 | 2020 | 40 | 0.170 |
Why?
|
| Interleukin-6 | 2 | 2019 | 241 | 0.160 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2020 | 23 | 0.160 |
Why?
|
| Interleukin-5 Receptor alpha Subunit | 1 | 2020 | 1 | 0.160 |
Why?
|
| Signal Transduction | 3 | 2019 | 689 | 0.160 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2010 | 50 | 0.160 |
Why?
|
| Progesterone Reductase | 1 | 2020 | 2 | 0.160 |
Why?
|
| Steroid Isomerases | 1 | 2020 | 2 | 0.160 |
Why?
|
| Leukocytes | 1 | 2020 | 57 | 0.160 |
Why?
|
| Multienzyme Complexes | 1 | 2020 | 18 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 175 | 0.160 |
Why?
|
| Triamcinolone | 1 | 2019 | 12 | 0.150 |
Why?
|
| Aging | 2 | 2016 | 955 | 0.150 |
Why?
|
| Influenza Vaccines | 2 | 2010 | 84 | 0.150 |
Why?
|
| Obesity | 4 | 2021 | 1179 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2019 | 837 | 0.150 |
Why?
|
| Pulmonary Emphysema | 1 | 2019 | 23 | 0.150 |
Why?
|
| Respiration Disorders | 1 | 2019 | 6 | 0.150 |
Why?
|
| Glycoproteins | 1 | 2019 | 36 | 0.150 |
Why?
|
| Phosphoproteins | 1 | 2019 | 48 | 0.150 |
Why?
|
| Influenza, Human | 2 | 2010 | 127 | 0.150 |
Why?
|
| Androstadienes | 2 | 2010 | 17 | 0.140 |
Why?
|
| Perioperative Nursing | 1 | 2018 | 2 | 0.140 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2018 | 34 | 0.140 |
Why?
|
| Cross-Sectional Studies | 6 | 2020 | 1584 | 0.140 |
Why?
|
| Death | 1 | 2018 | 53 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2010 | 213 | 0.130 |
Why?
|
| Tissue and Organ Procurement | 1 | 2018 | 99 | 0.130 |
Why?
|
| Prednisolone | 1 | 2017 | 9 | 0.130 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2016 | 7 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 622 | 0.120 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 475 | 0.120 |
Why?
|
| Child, Preschool | 3 | 2019 | 1282 | 0.120 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2016 | 54 | 0.120 |
Why?
|
| Risk Factors | 5 | 2021 | 4001 | 0.120 |
Why?
|
| Cross-Over Studies | 4 | 2019 | 98 | 0.120 |
Why?
|
| Research | 1 | 2015 | 76 | 0.110 |
Why?
|
| Disease Susceptibility | 2 | 2017 | 58 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2012 | 20 | 0.110 |
Why?
|
| Pregnenediones | 1 | 2014 | 1 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 541 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 950 | 0.110 |
Why?
|
| Cholecalciferol | 1 | 2014 | 22 | 0.110 |
Why?
|
| Bronchial Provocation Tests | 2 | 2011 | 5 | 0.100 |
Why?
|
| Respiratory Mechanics | 1 | 2013 | 6 | 0.100 |
Why?
|
| Vitamins | 1 | 2014 | 73 | 0.100 |
Why?
|
| Pneumonia | 1 | 2013 | 64 | 0.100 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 91 | 0.100 |
Why?
|
| Th1 Cells | 1 | 2013 | 25 | 0.100 |
Why?
|
| Skin Tests | 3 | 2010 | 12 | 0.100 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 682 | 0.090 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2012 | 15 | 0.090 |
Why?
|
| Genetic Variation | 3 | 2021 | 246 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2013 | 369 | 0.090 |
Why?
|
| Autoimmune Diseases | 1 | 2012 | 49 | 0.090 |
Why?
|
| Hispanic Americans | 3 | 2014 | 930 | 0.080 |
Why?
|
| Cholinergic Antagonists | 1 | 2010 | 10 | 0.080 |
Why?
|
| Membrane Glycoproteins | 1 | 2011 | 98 | 0.080 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2011 | 44 | 0.080 |
Why?
|
| Acetates | 1 | 2010 | 12 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2011 | 178 | 0.080 |
Why?
|
| Eosinophilia | 1 | 2010 | 11 | 0.080 |
Why?
|
| Quinolines | 1 | 2010 | 21 | 0.080 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2010 | 5 | 0.080 |
Why?
|
| Th2 Cells | 1 | 2010 | 9 | 0.080 |
Why?
|
| Proton Pump Inhibitors | 1 | 2010 | 11 | 0.080 |
Why?
|
| Infant | 1 | 2013 | 1083 | 0.080 |
Why?
|
| Linkage Disequilibrium | 4 | 2012 | 185 | 0.080 |
Why?
|
| Immunomodulation | 1 | 2010 | 29 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2011 | 251 | 0.080 |
Why?
|
| Gastroesophageal Reflux | 1 | 2010 | 20 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2011 | 138 | 0.080 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 43 | 0.080 |
Why?
|
| Discriminant Analysis | 1 | 2009 | 21 | 0.080 |
Why?
|
| Alleles | 2 | 2020 | 253 | 0.070 |
Why?
|
| Spirometry | 3 | 2019 | 30 | 0.070 |
Why?
|
| Vitamin D | 1 | 2010 | 189 | 0.070 |
Why?
|
| Biopsy | 2 | 2020 | 245 | 0.070 |
Why?
|
| Arginase | 1 | 2008 | 5 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 241 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2021 | 3460 | 0.070 |
Why?
|
| Linear Models | 3 | 2018 | 445 | 0.070 |
Why?
|
| Bronchoconstriction | 1 | 2007 | 2 | 0.070 |
Why?
|
| Airway Resistance | 1 | 2007 | 4 | 0.070 |
Why?
|
| Logistic Models | 3 | 2019 | 783 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 271 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 332 | 0.070 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2007 | 20 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2019 | 467 | 0.060 |
Why?
|
| Body Mass Index | 3 | 2017 | 909 | 0.060 |
Why?
|
| Airway Obstruction | 1 | 2006 | 32 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 183 | 0.060 |
Why?
|
| Prevalence | 2 | 2019 | 1003 | 0.060 |
Why?
|
| Delivery of Health Care | 1 | 2007 | 166 | 0.060 |
Why?
|
| Genotype | 2 | 2020 | 731 | 0.060 |
Why?
|
| Population Groups | 1 | 2004 | 7 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2004 | 22 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 1015 | 0.050 |
Why?
|
| Ethnic Groups | 1 | 2007 | 474 | 0.050 |
Why?
|
| Bronchial Hyperreactivity | 2 | 2015 | 16 | 0.050 |
Why?
|
| Metalloendopeptidases | 1 | 2003 | 11 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 142 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2014 | 156 | 0.050 |
Why?
|
| African Continental Ancestry Group | 1 | 2003 | 363 | 0.050 |
Why?
|
| Mice | 1 | 2008 | 2529 | 0.050 |
Why?
|
| Infusions, Parenteral | 1 | 2021 | 65 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 141 | 0.040 |
Why?
|
| Tumor Necrosis Factor Decoy Receptors | 1 | 2020 | 2 | 0.040 |
Why?
|
| Haplotypes | 3 | 2006 | 220 | 0.040 |
Why?
|
| Androgens | 1 | 2020 | 28 | 0.040 |
Why?
|
| Macrophages, Alveolar | 1 | 2019 | 11 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 290 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 28 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2019 | 12 | 0.040 |
Why?
|
| Cyclic AMP | 1 | 2019 | 45 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 99 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2019 | 59 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 2019 | 18 | 0.040 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2019 | 14 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 63 | 0.040 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2019 | 108 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2019 | 28 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2019 | 248 | 0.040 |
Why?
|
| Puberty | 1 | 2018 | 7 | 0.040 |
Why?
|
| Quality of Life | 2 | 2016 | 976 | 0.040 |
Why?
|
| Family | 1 | 2018 | 115 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2019 | 160 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2019 | 821 | 0.030 |
Why?
|
| RNA, Bacterial | 1 | 2016 | 3 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2016 | 20 | 0.030 |
Why?
|
| Animals | 1 | 2008 | 7599 | 0.030 |
Why?
|
| Chest Pain | 1 | 2019 | 223 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2017 | 185 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 14 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 292 | 0.030 |
Why?
|
| Pediatrics | 1 | 2018 | 156 | 0.030 |
Why?
|
| Bacteria | 1 | 2016 | 55 | 0.030 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 2015 | 2 | 0.030 |
Why?
|
| Education | 1 | 2015 | 37 | 0.030 |
Why?
|
| Disease Management | 1 | 2016 | 128 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2016 | 163 | 0.030 |
Why?
|
| Anxiety | 1 | 2016 | 195 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 499 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 527 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 189 | 0.030 |
Why?
|
| Interferon Regulatory Factor-2 | 1 | 2013 | 4 | 0.020 |
Why?
|
| STAT4 Transcription Factor | 1 | 2013 | 15 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 1152 | 0.020 |
Why?
|
| Depression | 1 | 2016 | 448 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2013 | 28 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 169 | 0.020 |
Why?
|
| Airway Remodeling | 1 | 2011 | 4 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2011 | 91 | 0.020 |
Why?
|
| Thrombospondins | 1 | 2011 | 6 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2011 | 43 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2011 | 16 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 3709 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2010 | 29 | 0.020 |
Why?
|
| Exhalation | 1 | 2010 | 3 | 0.020 |
Why?
|
| Beclomethasone | 1 | 2010 | 2 | 0.020 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2010 | 6 | 0.020 |
Why?
|
| Hospitalization | 1 | 2014 | 495 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 69 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2010 | 69 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 88 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2011 | 89 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 14 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 152 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 102 | 0.020 |
Why?
|
| Vaccination | 1 | 2010 | 146 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 1547 | 0.020 |
Why?
|
| Biological Availability | 1 | 2008 | 21 | 0.020 |
Why?
|
| Bronchoconstrictor Agents | 1 | 2007 | 1 | 0.020 |
Why?
|
| Methacholine Chloride | 1 | 2007 | 2 | 0.020 |
Why?
|
| London | 1 | 2007 | 2 | 0.020 |
Why?
|
| Lung Volume Measurements | 1 | 2007 | 4 | 0.020 |
Why?
|
| DNA Primers | 1 | 2007 | 89 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 199 | 0.020 |
Why?
|
| Base Sequence | 1 | 2007 | 249 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2006 | 29 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2006 | 137 | 0.020 |
Why?
|
| Time Factors | 1 | 2011 | 2195 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 497 | 0.010 |
Why?
|
| Netherlands | 1 | 2003 | 24 | 0.010 |
Why?
|
| ADAM Proteins | 1 | 2003 | 13 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2003 | 220 | 0.010 |
Why?
|